Bendamustine therapy in chronic lymphocytic leukemia

Abstract

Bendamustine combines alkylating properties with purine analogue properties making it an effective drug in chronic lymphocytic leukemia where agents that affect these pathways have proven useful. There is limited evidence of cross-reactivity with this agent and other pure purine analogues and alkylators.

Interaction of human organic anion transporter 2 (OAT2) and sodium taurocholate cotransporting polypeptide (NTCP) with antineoplastic drugs

“…Dixon plot analysis revealed the K i values of OAT2 for bendamustine, irinotecan and paclitaxel to be 43.3 ± 4.33 M, 26.4 ± 2.34 M and 10.4 ± 0.45 M, respectively. Bendamustine is increasingly being recognized as the frontline therapy for chronic lymphocytic leukemia (CLL) [20][21][22] and also in the treatment of other lymphomas [23,24]. Structurally bendamustine contains alkylating and antimetabolite (purine analog) groups.…”

Interaction of hepatic uptake transporters with antineoplastic compounds and regulation of the expression of organic cation transporter 3 in renal carcinoma cells

“…As we saw an interaction between the OAT2 and the compounds, bendamustine, irinotecan and paclitaxel, we set out to find whether they are inhibitors alone or they can be transported by OAT2. Bendamustine is increasingly being recognized as the frontline therapy for chronic lymphocytic leukemia (CLL) [167][168][169] and also in the treatment of other lymphomas [170;171]. Structurally bendamustine contains alkylating and antimetabolite (purine analog) groups.…”